Asset
PALAZESTRANT
OLEMA PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04505826 | phase1_2 | completed | 2020-08-13 | 2024-07-30 | Olema Pharmaceuticals, Inc. | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer |
| NCT05266105 | phase1 | active_not_recruiting | 2021-12-10 | 2026-03-01 | Olema Pharmaceuticals, Inc. | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients |
| NCT06016738 | phase3 | active_not_recruiting | 2023-11-16 | 2026-10-31 | Olema Pharmaceuticals, Inc. | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer |
| NCT07085767 | phase3 | recruiting | 2025-11-03 | 2028-12-01 | Olema Pharmaceuticals, Inc. | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer |
| NCT06784193 | phase1 | recruiting | 2024-12-16 | 2027-05-30 | Olema Pharmaceuticals, Inc. | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.